The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients
Objective: The objective of this study is to compute the potential benefit of Pramipexole ER on total levodopa equivalent dose (LED) and Unified Parkinson Disease Rating Score (UPDRS-III) compared to mono- or combined therapy of pramipexole IR and/or carbidopa/levodopa. Methods: This is a retrospect...
Saved in:
Main Authors: | Faddoul L (Author), Chahine B (Author), Haydar S (Author), Abourida S (Author), Hallit S (Author), Bou Raad E. (Author) |
---|---|
Format: | Book |
Published: |
Centro de Investigaciones y Publicaciones Farmaceuticas,
2018-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacoeconomic evaluation of pramipexole extended release monotherapy in early Parkinson's disease
by: D. Yu. Belousov, et al.
Published: (2018) -
3D Printed Mini-Floating-Polypill for Parkinson's Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy
by: Hellen Windolf, et al.
Published: (2022) -
Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease
by: Sharma VD, et al.
Published: (2018) -
Analysis of pramipexole dose–response relationships in Parkinson's disease
by: Wang Y, et al.
Published: (2016) -
Changes in Pramipexole Utilization after Introduction of the Extended-Release Formulation: A Nationwide Study in Taiwan
by: K. Arnold Chan, et al.
Published: (2020)